Bright Minds Biosciences, Inc. (DRUG)
52.43
+0.43
(+0.83%)
USD |
NASDAQ |
Oct 08, 16:00
52.00
-0.43
(-0.82%)
After-Hours: 20:00
Bright Minds Biosciences Enterprise Value : 296.01M for Oct. 7, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 07, 2026 | 296.01M |
| October 06, 2026 | 259.02M |
| October 05, 2026 | 274.21M |
| October 02, 2026 | 283.09M |
| October 01, 2026 | 268.49M |
| September 30, 2026 | 274.50M |
| September 29, 2026 | 273.71M |
| September 28, 2026 | 292.65M |
| September 25, 2026 | 294.04M |
| September 24, 2026 | 310.90M |
| September 23, 2026 | 354.40M |
| September 22, 2026 | 381.53M |
| September 21, 2026 | 369.59M |
| September 18, 2026 | 384.59M |
| September 17, 2026 | 390.21M |
| September 16, 2026 | 366.14M |
| September 15, 2026 | 377.09M |
| September 14, 2026 | 408.26M |
| September 11, 2026 | 406.29M |
| September 10, 2026 | 424.24M |
| September 09, 2026 | 424.83M |
| September 08, 2026 | 443.08M |
| September 04, 2026 | 425.82M |
| September 03, 2026 | 454.03M |
| September 02, 2026 | 484.61M |
| Date | Value |
|---|---|
| September 01, 2026 | 481.85M |
| August 31, 2026 | 490.63M |
| August 28, 2026 | 501.28M |
| August 27, 2026 | 518.30M |
| August 26, 2026 | 538.96M |
| August 25, 2026 | 567.17M |
| August 24, 2026 | 542.86M |
| August 21, 2026 | 546.75M |
| August 20, 2026 | 558.00M |
| August 19, 2026 | 618.96M |
| August 18, 2026 | 612.05M |
| August 17, 2026 | 567.07M |
| August 14, 2026 | 537.09M |
| August 13, 2026 | 552.47M |
| August 12, 2026 | 565.99M |
| August 11, 2026 | 574.67M |
| August 10, 2026 | 580.00M |
| August 07, 2026 | 565.59M |
| August 06, 2026 | 580.09M |
| August 05, 2026 | 572.20M |
| August 04, 2026 | 546.06M |
| August 03, 2026 | 510.85M |
| July 31, 2026 | 505.72M |
| July 30, 2026 | 519.23M |
| July 29, 2026 | 484.02M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Amgen, Inc. | 266.63B |
| Lineage Cell Therapeutics, Inc. | 190.01M |
| Recursion Pharmaceuticals, Inc. | 1.796B |
| Agenus, Inc. | 587.26M |
| BioCryst Pharmaceuticals, Inc. | 2.628B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.732M |
| Total Expenses (Quarterly) | 1.732M |
| EPS Diluted (Quarterly) | -0.1762 |
| Earnings Yield | -3.98% |
| Normalized Earnings Yield | -3.975 |